Trial Profile

A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults With Inoperable Relapsed or Refractory High-Grade Glioma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Mar 2025 Status changed from recruiting to active, no longer recruiting.
27 Mar 2024 According to a Cellectar Biosciences media release, study is supported by a $2 million Fast Track SBIR grant from the National Institute of Health's National Cancer Institute (NCI), which was awarded based in part on the promising Phase 1a trial data.
30 Jan 2024 According to a Cellectar Biosciences media release, today announced the first patient has been enrolled in its Phase 1b clinical trial evaluating iopofosine I 131.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com